Summary
Thermo Fisher Scientific Inc. (TMO) filed an 8-K on April 27, 2010, to report the issuance of $750 million in new senior notes. This offering comprised $450 million of 3.200% Senior Notes due 2015 and $300 million of 4.700% Senior Notes due 2020. The proceeds from this issuance are earmarked for significant debt management activities, including redeeming outstanding Floating Rate Convertible Senior Debentures due 2033 and calling all outstanding 6 1/8% Senior Subordinated Notes due 2015. This strategic move indicates a focus on optimizing the company's capital structure by potentially lowering interest expenses and simplifying its debt profile. The new notes are unsecured general obligations, senior to subordinated debt but effectively subordinated to secured debt and liabilities of subsidiaries. The indenture includes covenants restricting the incurrence of secured debt, sale-leaseback transactions, and asset sales, along with provisions for acceleration of debt upon default and a change of control put option under specific downgrade conditions.
Key Highlights
- 1Issuance of $450 million in 3.200% Senior Notes due 2015.
- 2Issuance of $300 million in 4.700% Senior Notes due 2020.
- 3Total gross proceeds from the note offering expected to be approximately $741.8 million after expenses.
- 4Use of proceeds includes redemption of Floating Rate Convertible Senior Debentures due 2033 (up to $226.5 million).
- 5Use of proceeds includes redemption of all outstanding 6 1/8% Senior Subordinated Notes due 2015 on July 1, 2010 (approximately $515.3 million).
- 6Notes are general unsecured obligations, senior to subordinated debt.
- 7Indenture contains covenants restricting secured debt, sale-leaseback transactions, and mergers/asset sales.